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Alzheimer’s disease (AD) is a debilitating form of dementia. The hallmark protein associated with the disease is the amyloid beta
(Aβ) peptide. Aggregation of Aβ has been shown to depend on interactions with metals. The recent studies now demonstrate
that metals also play additional important roles in the disease process. Consequently, there may be beneﬁt from modulating metal
homeostasis.However,theroleandsubcellularlocationofmetalswithinneuronsisnotwell understood.Thereisgrowingevidence
to suggest that metals can act at the site of cellular membrane receptors and aﬀect cellular signaling by modulating the signal
transduction of those receptors. The glutamatergic and cholinergic receptor systems, both well-known neurotransmitter systems
aﬀected in AD, have well-documented metal interactions, as do the tropomyosin-receptor kinase (Trk) family of receptors and
the epidermal growth factor (EGF) receptor. In this paper, the metal interactions with these membrane receptor systems will be
explored and thus the potential for membrane receptors as an intervention point in AD will be assessed.
1.Introduction
Alzheimer’s disease (AD) is the most common form of age-
related dementia [1, 2]. The key neuropathological features
include extracellular amyloid beta (senile) plaques (Aβ),
intracellular neuroﬁbrillary tangles, chronic oxidative stress,
and disease progression leading to cognitive decline and
eventually neuronal cell loss [1, 2]. The cognitive decline
observedinADhasitsrootsatthesynapse,thespacebetween
neurons, through which they communicate. The synapse
is also the site at which the Aβ peptide, the characteristic
amyloid protein associated with AD, is believed to ﬁrst
deposit [2]. It is also the site where Aβ may interact
with metals released as a consequence of glutamatergic
transmission. In the recent years, growing evidence points to
soluble Aβ oligomers being the toxic species [3]a n dw h o s e
appearance correlates with disease progression [4, 5]. It has
also been hypothesized that small oligomers as opposed to
Aβ ﬁbrils induce synaptic failure [6, 7], after experiments
showed Aβ oligomers to inhibit long-term potentiation
(LTP) [8–10], a biochemical model of synaptic strength
[11]. Furthermore, early memory loss associated with the
disease has been attributed to synapse loss occurring prior to
neuronal cell death [6, 7], and there are reports of a decrease
in synaptic protein levels in AD [12].
2.Metals, Aging,and Alzheimer’sDisease
The ability of life to utilize oxygen is dependent on the
chemistry of transition metal ions. Metal ions are able
to coordinate O2 enabling transport, and the ability of
transition metal ions to move between various oxidation
states allows the activation and ultimately utilization of
oxygen. If not properly regulated the same chemistry that
allows the transport and utilization of oxygen can have the
potential to generate reactive oxygen species (ROS). Metals
are integral for the function of enzymes and numerous
intracellular signaling proteins, and in a healthy individual,
the levels of these metals are highly regulated. With normal2 International Journal of Alzheimer’s Disease
aging and more so in a neurodegenerative disease state,
such homeostatic mechanisms are postulated to become
perturbed, leading to aberrant metal-dependant enzyme
function, mitochondrial dysfunction, and the production of
ROS, all of which are well-known aetiologies associated with
AD.
The transition metals implicated in AD include copper
(Cu), zinc (Zn), and iron (Fe) [13]. These metals are
generallyfoundligand-bound,andnotasfreeions.Although
there do exist pools of metal that are coordinated to lower
aﬃnity ligands and as such are readily exchangeable. There
is increasing evidence to suggest that Cu and Zn may exist
as free ions when released into the synapse as part of
the synaptic transmission process (reviewed in [1]). These
metals can reach up to micromolar levelsin the synaptic cleft
[1], with Cu reaching 15μM but Zn reaching up to 300μM
in the mossy ﬁbres of the hippocampus postaction potential
input [1, 14].
Aging is the main risk factor associated with all neurode-
generative diseases. Metal dyshomeostasis is an important
feature of AD and this may be related to aging. There
is an apparent state of intracellular Cu deﬁciency and an
extracellular increase in Cu and Zn, possibly due to the
metals binding to Aβ (reviewed in [1]). Binding of metals to
Aβ canpromote aggregation ofthe peptidewith pathological
consequences [15].
I nt h ec a s eo fA D ,t h em o s tc o m m o nf o r mo fa g e - r e l a t e d
dementia [16, 17], a state of Cu imbalance, can also lead
to a dysfunction of vital cuproenzymes such as cytochrome
c oxidase (COX) of the electron transport chain, as well as
antioxidantssuch assuperoxide dismutase (SOD1),resulting
in oxidative stress via the generation of reactive oxygen
species (ROS). Fe levels are also increased in the neuropil
of the AD brain [13] and can contribute to the production
of ROS and oxidative stress. Oxidative stress can ultimately
result in neuronal cell dysfunction, which can lead to a lack
of synaptic transmission.
There is growing evidence that suggests metals are able
to act on receptors at the cell membrane with the hypothesis
being that altered metal homeostasis aﬀects cell signaling
due to outside-in signal transduction. In this paper, known
metal interactions with relevant membrane receptors will be
discussed and potential therapeutic implications to AD will
be assessed.
3.The GlutamatergicSystemand AD
The major neurotransmitter at excitatory synapses in the
brain is glutamate. The glutamatergic system of synaptic
transmission contains ionotropic and metabotropic glu-
tamate receptors, with the latter lacking a channel for
ion ﬂux but instead glutamate binding induces a change
in the intracellular domain of the receptor, allowing for
intracellular signaling. Failure in glutamatergic transmission
is common in most neurodegenerative diseases, including
AD [18].
The ionotropic glutamate receptors are divided into
N-methyl-D-aspartate (NMDA) and non-NMDA receptors
with both receptor classes allowing the ﬂux of ions whereby
an electrical signal is translated into a chemical signal.
The non-NMDA receptors (non-NMDARs) are α-amino-
3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) and
kainate receptors, with AMPA receptors (AMPARs) being
responsible for fast and transient synaptic transmission.
The role of the kainate family of ionotropic receptors
is less well understood however they are present pre-
and post-synaptically and maybe involved in neuron-glia
signaling [19], as well as being involved in the modulation
of synaptic transmission and plasticity [20]. Activation
of NMDARs by presynaptically released glutamate causes
calcium (Ca2+)e n t r yw h i c ha c t i v a t e st h eC a 2+ depen-
dant kinase, Ca2+/calmodulin dependent-protein kinase II
(CaMKII) [21]. The activated CaMKII associates with the
NMDAR, leading to AMPAR phosphorylation [21–23].
This event encourages greater channel conductance of the
AMPAR, and more importantly AMPAR insertion upon an
LTP-inducing stimulus [21, 24, 25]. Soluble Aβ oligomers
bind to NMDAR in AD [26] and induce NMDAR internal-
ization [27]. There is further work indicating that binding
of CaMKII to the NMDAR channel is required for LTP
induction [28].
NMDARs are reported to interact directly with a suite
of intracellular proteins, adhesion and signaling molecules,
such as CaMKII,neuronalnitric oxidesynthase (nNOS),and
F-actin (see [29]) and indirectly inﬂuence the activation of
cAMP response element-binding (CREB) and brain-derived
neurotrophicfactor(BDNF)(see[30])aswell asintracellular
kinases such as extracellular signal regulated kinase (ERK),
glycogen synthase kinase 3 (GSK3), and Akt.
There is evidence to suggest that the NMDAR interacts
with amyloid peptides and their precursor proteins. For
example, patch clamp recordings of primary hippocampal
cultures from APP KO mice showed increased NMDAR-
mediated EPSCs [31]. Aβ has both direct and indirect
interactions with the receptor. It is postulated, as described
earlier, that small oligomeric species are the key toxic
elements in numerous amyloid diseases, such as AD [3].
These species have been shown to colocalize with the NR2B
NMDAR subunit in rat hippocampal slices [32]. These
species, as well as the Aβ peptide itself, interact with the
NMDAR and can induce an increase in intracellular Ca2+.
This in turnleadsto membranepermeabilisation, a common
phenomena when amyloid proteins interact with the cell
membrane [33–36]. Aβ can also propagate the loss of
NMDARs from the cell surface [37]. A loss of NMDARs
from the synapse has been found in AD brains [38, 39].
Hoey et al. also recently reported that activation of synaptic
NMDARs promoted α-secretase mediated APP processing
and inhibited Aβ production in mouse primary cortical
neurons [40].
It has been shown that diﬀerent Aβ oligomers can exert
diﬀerent aﬀects. In in vitro studies looking at the dentate
gyrus, Aβ1–40 was found to selectively increase NMDAR-
mediated transmission, whereas Aβ1–42 has been shown to
reduce NMDAR-mediated synaptic currents in the dentate
gyrus[41, 42]. Thusit is apparent that Aβ isable to inﬂuence
glutamatergic transmission via the NMDAR.International Journal of Alzheimer’s Disease 3
DuetotheimplicationofNMDARsinneurodegenerative
diseases, and especially AD, drugs that exploit the properties
ofthe receptor have beendevelopedas potential therapeutics
for the disease. Excitotoxicity, caused by overstimulation of
NMDARs due to excessive glutamate release, is a common
cause of neuronal loss in most neurological insults including
stroke as well as neurodegenerative diseases, such as AD
[43].Asaresult,NMDARantagonistshavebecomeattractive
therapeuticsforthepotentialtreatmentofthesediseaseswith
memantine being utilized clinically, to treat AD patients.
4.The GlutamatergicSystemand Metals
The most extensive work done examining the glutamatergic
system and transition metals is via study of the NMDAR
and its metal interactions. Metals, especially Cu and Zn,
have been shown to have a modulatory eﬀect on NMDAR
function within the glutamatergic system.
Zn is coreleased along with glutamate into the gluta-
matergicsynapse [44–46],thusitsroleinsignalingwithin the
brain may best be assessed in its role as a neurotransmitter. It
is well documented that the NMDAR possesses an inhibitory
Zn binding site on the NR2 subunit [47–50]. The equi-
librium dissociation constant (Kd)o fZ nf o rt h eN M D A R
was reported to be 13μM[ 51] but almost a decade later
extracellular Zn concentrations as low as 3nM were shown
to be inhibitory of NR1-NR2A containing receptors [50].
Zn inhibits the NMDAR in both a voltage-dependent and -
independentmanner with theaﬃnity being higher in thelat-
ter, inferring that Zn binds at a diﬀerent site on the receptor
to the voltage-dependentmagnesium (Mg)channel blocking
site. Also, the IC50 of the voltage-independent Zn inhibition
is 50-fold lower in NR1-NR2A containing receptors than
NR1-NR2B containing receptors [50]. Zn released from
excitatory synapses in the hippocampus inhibits NMDARs
[52, 53]. Furthermore, synaptic Zn entry via glutamate
receptors into neurons in the CA3 region of the hippocam-
pus evokes LTP [54]. Interestingly, in the CA1 region of the
rat hippocampus, synapses containing presynaptic vesicular
Zn showed a decrease in postsynaptic AMPAR subunit levels
whilstNMDARlevelswereunchanged[55].Thisimpliesthat
vesicular Zn could confer the behavior of a synapse during
synaptic transmission, further cementing the modulatory
role that Zn plays at the glutamatergic synapse.
A known interaction of the NMDAR with metals, is the
role it plays in Cu homeostasis within the cell. Schlief and
Gitlin have developed a model based on experiments in
mousehippocampalneurons[56].UponNMDARactivation
by glutamate, Ca2+ enters into the cell, as previously dis-
cussed. This increase in Ca2+ within the cell having activated
an intracellular signaling cascadeinduces theMenkesATPase
protein to translocate to a membrane bound compartment
to generate and replenish a readily releasable pool of Cu. An
increase in Ca2+ as a result of NMDAR activation can act
uponthisnovelpoolandcausetheextracellularreleaseofCu.
This released free Cu can then act back upon the NMDAR in
a functionally negative feedback fashion, to inhibit Ca2+ ﬂux
and inhibit further Cu release. The MenkesATPase protein is
required for Cu eﬄux [56], and translocation of the protein
as a result of NMDAR activation creates a link between
NMDAR activation and Cu homeostasis.
Further work from Schlief et al. demonstrated that Cu
treatment of hippocampal neurons showed a decrease in
the elevation of intracellular Ca2+,w i t h o u ta ﬀecting the
localization or distribution of NMDARs, suggesting that Cu
has a direct eﬀect on NMDAR function [57]. As Cu2+ is
a potent electron acceptor, it can potentially catalyze S-
nitrosylation of NMDARs,resulting in a loss ofsecretable Cu
as in the case of Menkes Disease. This then leaves the cell
deﬁcient in controlling NMDAR activation which may lead
to an increase in Ca2+ [56]. LTP studies onthe CA1 region of
rat hippocampus showed reduced EPSCs by low micromolar
Cu concentrations [56].
Cu is released post-synaptically [58, 59]w h e r ea sZ ni s
believed to be co-released with glutamate, presynaptically,
into the synaptic cleft [60]. Cu and Zn can reach micromolar
concentrations within the synaptic cleft (see above) as
compared to glutamate which can reach low millimolar
concentrations after excitatory synaptic transmission [56].
These data taken together suggest that metals play an
important role in modulating NMDAR function.
5.The Cholinergic Systemand AD
Acetylcholine (ACh) is a neurotransmitter, which is impor-
tant in learning and memory networks [61, 62]. Cholinergic
receptors are receptors that respond to ACh. Cholinergic
receptors are divided into two categories, depending on
their exogenous agonists. This includes nicotinic recep-
tors (nAChR) whose exogenous agonist is nicotine, and
muscarinic receptors (mAChR) whose exogenous agonist is
muscarine. Both nAChRs and mAChRs are found in the
central nervous system and in the periphery; however the
neuronal subclasses of each receptor type will be discussed
in this paper.
Along with hallmark pathologies associated with AD for
example, presence of high levels of Aβ,t h e r ea r ea l s ok n o w n
d e ﬁ c i t si nt h ec h o l i n e r g i cs y s t e mi nt h eA Db r a i n[ 63–65].
Brain regions highly aﬀected in AD, as the neocortex and the
hippocampus have signiﬁcant changes to their cholinergic
innervation [64]. There are several reports of a loss of
cholinergic ﬁbers and terminals in AD, as well as reductions
in cholinergic receptors [64, 66, 67]. The activities of the
two major cholinergic enzymes, choline acetyltransferase
(ChAT) and acetylcholinesterase (AChE), are reported to be
decreasedinAD[68–70].ReductionsinChATactivityarethe
greatest [71, 72] and correlate with disease severity [68, 73].
Thebasal forebrainis where theorigins ofthecholinergic
neurons innervating the cortex lie. It is widely reported
that there is a loss of these cholinergic basal forebrain
neurons in the AD brain [69, 74, 75]. There is uncertainty
h o w e v e r ,i ft h i sn e u r o nl o s so c c u r sa sr e s u l to fA β toxicity
on the cortical cholinergic terminals causing retrograde
degeneration, or if the loss of cholinergic basal forebrain
neurons is a primary consequence of Aβ toxicity, with the
loss of cortical cholinergic innervation being a secondary4 International Journal of Alzheimer’s Disease
consequence. Numerous transgenic mouse models and cell
lines have been used to attempt to delineate this. In aged
APP23 mice, there was a signiﬁcant decrease in cortical
cholinergic ﬁber length but no loss of cholinergic basal
forebrain neurons when compared with aged-matched wild-
type neurons suggesting that deﬁcit of cortical cholinergic
innervation in these mice is a local eﬀect of Aβ which is
not caused by deﬁcit of cholinergic basal forebrain neurons
[72]. A signiﬁcant decrease in ChAT activity in the tissue of
APP23 mice with no signiﬁcant eﬀect on AChE levels, when
compared with aged-matched wild-type mice was shown.
Similar results were reported by Pedersen et al. where a
decrease in the activity of ChAT was observed with no eﬀect
onAChEactivityinSN56cells,amousecelllinederivedfrom
basal forebrain cholinergic neurons [71]. They also showed
Aβ1–42 suppressed the synthesis of ACh in a nontoxic
manner with this reduction being prevented by cotreatment
with all-trans-retinoic acid, a compound formerly shown
to increase mRNA expression of ChAT in these cells [71],
indicating that Aβ can have non toxic eﬀects on the basal
forebrain cholinergic neurons.
Aβ h a sa l s ob e e ns h o w nt ob i n dt on e u r o n a lα7 nicotinic
ACh (α7nACh) receptors with high aﬃnity [76, 77]w h i c h
can cause a suite of toxic consequences. As previously
discussed Aβ binding to the NMDAR can cause inter-
nalization of the NMDAR and inhibit LTP. Snyder et al.
reported α-bungarotoxin, a speciﬁc α7nACh antagonist, to
reduce Aβ-induced NMDAR internalization, suggesting that
NMDAR function may be negatively aﬀected by an Aβ-
α7nACh interaction [27]. Wang et al. recently showed in
synaptosomes prepared from both AD postmortem tissue
as well as frontal cortex slices from postmortem tissue
exposed to Aβ1–42 that S 24795, a partial α7nACh agonist,
can release Aβ from the Aβ-α7nACh complex allowing for
partial recovery of function of the α7nACh and the NMDAR
[78]. This demonstrated that disruption of the Aβ-α7nACh
interaction may be a mean of reducing pathophysiological
features of AD.
6.The CholinergicSystemandMetals
There are a few reports of lead (Pb), aluminium (Al), and
cadmium (Cd) having an eﬀect on the cholinergic system in
vitro and in vivo [79–81].
As Pb exposure can produce poor learning and deﬁcits
in intelligence tests [82], the interaction of Pb with the
cholinergic system has been studied extensively as a mean
of discovering the mechanism of toxicity of Pb in the brain
which causes these neurological eﬀects.
There are conﬂicting reports, however, ontheaﬀectofPb
on the cholinergic system. Moingeon et al. reported that an
acute in vivo treatment of rats with the metal inhibits ACh
turnover, decreases ACh content in certain brain regions,
and induces a reversible increase in mAChRs in the striatum
and cortex [83]. However, this latter ﬁnding is refuted by
Schulte et al., where they had found there to be no major
eﬀect of Pb on mAChRs in the frontal cortex of mouse brain
[84]. This ﬁnding was supported by Gotti et al., using an
in vitro model of both diﬀerentiated and undiﬀerentiated
cholinergic neurons [85]. They also found that Pb increased
the number of nAChR binding sites, although Costa and Fox
had reported that chronic Pb exposure to decrease mAChRs
in the visual cortex alone of neonatal rats [79]. It is apparent
that the eﬀect that Pb has on the cholinergic system is very
much dependant on the type of cholinergic receptor studied.
Al increased the number of mAChRs in cholinergically
diﬀerentiated IMR32 cells, a human neuroblastoma cell
line, whereas it had no eﬀect on nAChRs, as measured by
α-bungarotoxin binding sites [85]. However Johnson and
Jope reported Al reduced the eﬀects of an in vitro ACh
agonist, carbachol [80]. In the same paper, Cd increased
both the mAChR and nAChR expressions in cholinergically
diﬀerentiated and undiﬀerentiated IMR32 cells.
As discussed, there are few studies investigating the role
of cholinergic receptors and metals, and of those that do,
few give conclusive outcomes and did not investigate other
metals associated with AD pathology such as Cu and Zn. As
a result, more work is required to determine if metals could
play a role in mediating the cholinergic deﬁcits associated
with AD.
7.TrkB Receptorsand AD
Tropomyosin-receptor kinase (Trk) receptors are necessary
for the survival, diﬀerentiation, and maturation of the
developing brain [86]. Trk receptors have been shown to
play a role in synaptic plasticity as well as in modulating
synaptic transmission [87, 88]. Furthermore a Trk receptor
family variant, the TrkB receptor, has been reported to be
important forLTP inCA1neurons [89, 90]. The endogenous
agonists for TrkB receptors are brain-derived neurotrophic
factor (BDNF) and neurotrophin-4/5 (NT-4/5), with BDNF
being speciﬁc for TrkB receptors [91].
TrkB activation was traditionally believed to be via
neurotrophin binding, inducing TrkB receptor dimerisation
leading to phosphorylation of the cytoplasmic tyrosine
kinase tails. This mediates an elaborate signaling cascade
ultimately resulting in antiapoptotic outcomes [91, 92].
However Lee et al., showed that TrkB signaling can occur
independently of neurotrophin binding, through what is
known as “transactivation” by G protein-coupled receptor
(GPCR) ligands for example, adenosine and PACAP. Follow-
up studies revealed the role of Src kinase-tyrosine phos-
phorylation in intracellularly activating cell membrane and
intracellular TrkB receptors [93, 94].
There are reports of the TrkB receptor-BDNF pathway
being compromised in AD. In the hippocampus of AD
patients, a decrease in BDNF protein levels [95]a sw e l l
as a reduction in BDNF mRNA levels [96, 97] has been
reported. AdecreaseinBDNFproteinlevelsintheentorhinal
and temporal cortex of AD suﬀers has also been described
[98]. Abnormal TrkB expression of full length and truncated
forms and altered distribution has been found in AD brains
[95, 99]. Ferrer et al. reported various changes in BDNF,
including truncated TrkB and full length TrkB in glial
cells, in neurons with hyperphosphorylated tau tangles andInternational Journal of Alzheimer’s Disease 5
dystrophic neurons surrounding Aβ plaques from brains of
individuals with severe AD [100].
Although the most widely studied Trk receptor is the
TrkB receptor, recently Capsoni et al. (2010) reported that
TrkA beneﬁcially activates Aβ accumulation in a transgenic
mouse model and discusses the role of proNGF, NGF, and
TrkA versus p75 neurotrophin receptor (p75NTR) in AD
neurodegeneration [101].
8.TrkBReceptorsandMetals
There have been few studies looking into a possible role
for metals in TrkB signaling. Jung et al. reported that
treatment of cortical neuron cultures with micromolar Zn
concentrations can robustly activate TrkB as well as kinases
downstream of the receptor, such as Src, ERK, and Akt
[102]. The mechanism of Zn activating TrkB was found to
be an extracellular one, mediated by activation of matrix
metalloproteinases (MMPs) causing release of pro-BDNF by
the cells, which then gets converted to mature BDNF by
extracellular MMPs [93, 102]. In support of this, recently
Corona [103] reported the protective role of dietary Zn
supplementation in a transgenic mouse model of AD, where
Zn appeared to increase BDNFsignaling by MMP activation.
In vitro,i nP C 1 2c e l l s ,Z nh a sb e e ns h o w nt oi n h i b i tn e u r i t e
outgrowth by BDNF [104] but in cortical cultures, this
inhibition was only slight, revealing that the activation by Zn
overrides the potential BDNF/TrkB inhibitory eﬀect [102].
Thus, Zn release from the glutamatergic synapse could play
an important role in activity-dependant activation of TrkB.
The same group later reported that Cu too was able
to activate TrkB in cortical neuron cultures in an MMP
dependentfashion [105] .C u ,l i k eZ n ,w a sa b l et oa c t i v a t eS r c
kinase, ERK, and Akt and increased the activity of MMP2
and MMP9, thereby catalyzing the conversion of pro BDNF
to mature BDNF [105]. They proposed that if Cu is released
at the synapse post-depolarisation as postulated by Hartter
and Barnea then as with Zn, there maybe physiologically
beneﬁcialeﬀectsthat couldbe mediated byboth metals, such
as activation of TrkB signaling [58].
Huang et al. reported for the ﬁrst time the ability of
Zn released by stimulated CA3 hippocampal neurons to
transactivate TrkB in vivo via Src kinase [106]. The activated
TrkB receptors then play an important role in LTP at
the mossy ﬁber-CA synapse. As previously discussed, TrkB
receptor signaling has been reported to be important in
hippocampal CA1 LTP, but this study puts forward a link
between Zn, TrkB, and hippocampal CA3 LTP. With LTP
known to be inhibited in AD, in an Aβ-NMDAR associated
manner, assessing the Zn, TrkB, and LTP link may provide an
interesting opportunity for therapeutic intervention in AD.
9. Membrane Receptors, Metals, and
ImplicationsforAD
The membrane receptor systems described so far have
proposed roles in AD, and therefore metal interactions with
these membrane receptor families could provide beneﬁcial
modulatory and intervention points, in the pursuit of the
amelioration of AD pathology. Work done within our group
hasshown thatCuandZn,deliveredintothecellbythemetal
chaperones CQ, PBT2, and CuGTSM, can cause activation
of phosphatidylinositol 3-kinase (PI3K) and the consequent
phosphorylation of Akt and GSK3 and the subsequent
activation of MAPK (ERK), all kinases previously discussed
as having antiapoptotic eﬀects. This caused activation of
MMP2 leading to extracellular Aβ degradation [107–109].
CQ and PBT2 are 8-hydroxyquinoline metal ligands.
CuGTSM belongs to the metal bisthiosemicarbazone (M-
BTSC) family of metal-based drugs. They are stable, of a low
molecular weight, neutral and most importantly capable of
crossing cell membranes [108]. Due to their versatility in
vitro, their use has been widely adopted within our group.
CuGTSM has demonstrated therapeutic eﬀects in an AD
mouse model and was found to aﬀect cellular signalling
pathways central to AD as well as the amyloid proteins, Aβ
and tau [109].
Price et al. reported CQ coordinated to Cu activated epi-
dermal growth factor receptor (EGFR) in epithelial cells and
neurons [110]. Thisactivation, byphosphorylation ofEGFR,
did not require EGF orTGF-α making it ligand independent.
The phosphorylation was mediated by Src kinase and was
speciﬁc for Cu. Interestingly however, activation of EGFR
by CQ coordinated to Cu resulted in the activation of ERK
only, with no eﬀects on PI3K-Akt or JNK but still resulted in
Aβ degradation by MMP activation. This would infer that
activation of ERK by intracellular bioavailable metals is a
necessary step in Aβ degradation, mediated by upregulation
of MMP.
We later reported the EGFR activation by CuGTSM and
ZnBTSCs in a glial cell line as well, but CuGTSM, in contrast
to CQ coordinated to Cu, did not phosphorylate EGFR in a
Src kinase-mediated manner, rather CuGTSM inhibited the
activity of protein tyrosine phosphatase (PTP). CuGTSM, as
with CQ coordinated to Cu, did however induce activation
of PI3K-Akt-GSK3, ERK, and JNK [111].
Whilst EGFR has not directly been linked to AD, the
pathway downstream of the receptor being activated by
an increase in intracellular Cu and Zn involves kinases
associated with AD and appears to be rather similar to TrkB
signalling. Thus EGFR and its metal interactions could be
an interesting area to investigate and provide clues on other
possible membrane receptors aﬀected in AD.
10.Conclusion
In conclusion, an imbalance of transition metal levels in the
AD brain plays a neurotoxic role, but how and where this
imbalance aﬀects signaling are not known. However, their
interactions with membrane receptors in the glutamatergic
system, TrkB and EGF signaling system, and to a lesser
extent in the cholinergic system infer a potentially important
eﬀectonADthroughthesemembrane receptorsystems. This
may involve a combination of eﬀects including inhibitory,
modulatory or activation of membrane receptor-mediated
functions that have an important role in AD. Therefore it is6 International Journal of Alzheimer’s Disease
likely that the link between metals and membrane receptors
may oﬀer a unique point of intervention in AD.
Acknowledgments
P. Amadoruge is the recipient ofThe George HicksPostgrad-
uate Scholarship for Dementia Prevention and Risk Reduc-
tion Research-Alzheimer’s Australia Victoria, The George
Hicks Foundation and Alzheimer’s Australia Research. The
authors would like to thank Dr. Anthony White for his help
and review of this paper. This work was funded by the
National Health and Medical Research Council of Australia
and the Australian Research Council.
References
[1] A. I.Bush,“Drug developmentbased on the metalshypothe-
sis of Alzheimer’s disease,” Journal of Alzheimer’s Disease,v ol.
15, no. 2, pp. 223–240, 2008.
[ 2 ]R .D .T e r r y ,E .M a s l i a h ,D .P .S a l m o ne ta l . ,“ P h y s i c a lb a s i s
of cognitive alterations in Alzheimer’s disease: synapse loss
is the major correlate of cognitive impairment,” Annals of
Neurology, vol. 30, no. 4, pp. 572–580, 1991.
[ 3 ]D .M .W a l s ha n dD .J .S e l k o e ,“ O l i g o m e r si nt h eb r a i n :t h e
emerging role of soluble protein aggregates in neurodegener-
ation,”ProteinandPeptide Letters,vol.11,no.3,pp. 213–228,
2004.
[ 4 ]Y .M .K u o ,M .R .E m m e r l i n g ,C .V i g o - P e l f r e ye ta l . ,“ W a t e r -
solubleAβ (N-40, N-42) oligomersin normaland Alzheimer
disease brains,” Journal of Biological Chemistry, vol. 271, no.
8, pp. 4077–4081, 1996.
[ 5 ]L .F .L u e ,Y .M .K u o ,A .E .R o h e re ta l . ,“ S o l u b l ea m y l o i dβ
peptide concentration as a predictor of synaptic change in
Alzheimer’s disease,” American Journal of Pathology, vol. 155,
no. 3, pp. 853–862, 1999.
[ 6 ]W .L .K l e i n ,G .A .K r a ﬀt ,a n dC .E .F i n c h ,“ T a r g e t i n g
small A β oligomers: the solution to an Alzheimer’s disease
conundrum?” TrendsinNeurosciences,vol.24,no.4,pp.219–
224, 2001.
[7] J. Hardy and D. J. Selkoe, “The amyloid hypothesis of
Alzheimer’s disease: progress and problems on the road to
therapeutics,” Science, vol. 297, no. 5580, pp. 353–356, 2002.
[ 8 ] M .P .L a m b e r t ,A .K .B a r l o w ,B .A .C h r o m ye ta l . ,“ D i ﬀusible,
nonﬁbrillar ligands derived from Aβ are potent central
nervous system neurotoxins,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 95,
no. 11, pp. 6448–6453, 1998.
[9] D. M. Walsh, I. Klyubin, J. V. Fadeeva et al., “Naturally
secreted oligomers of amyloid β protein potently inhibit
hippocampal long-term potentiation in vivo,” Nature,v o l .
416, no. 6880, pp. 535–539, 2002.
[10] H. W.Wang,J.F. Pasternak,H. Kuo et al.,“Soluble oligomers
of β amyloid (1–42) inhibit long-term potentiation but not
long-term depression in rat dentate gyrus,” Brain Research,
vol. 924, no. 2, pp. 133–140, 2002.
[11] T. V. P. Bliss and A. R. Gardner Medwin, “Long lasting
potentiation of synaptic transmission in the dentate area
of the unanaesthetized rabbit following stimulation of the
perforant path,” Journal of Physiology, vol. 232, no. 2, pp.
357–374, 1973.
[ 1 2 ]P .H .R e d d y ,G .M a n i ,B .S .P a r ke ta l . ,“ D i ﬀerential loss
of synaptic proteins in Alzheimer’s disease: implications for
synaptic dysfunction,” Journal of Alzheimer’s Disease,v o l .7 ,
no. 2, pp. 103–117, 2005.
[13] M. A. Lovell, J. D. Robertson, W. J. Teesdale, J. L. Campbell,
and W.R. Markesbery, “Copper, ironand zincinAlzheimer’s
disease senile plaques,” Journal of the Neurological Sciences,
vol. 158, no. 1, pp. 47–52, 1998.
[ 1 4 ]C .J .F r e d e r i c k s o n ,M .A .K l i t e n i c k ,W .I .M a n t o n ,a n dJ .B .
Kirkpatrick, “Cytoarchitectonic distribution of zinc in the
hippocampus of man and the rat,” Brain Research, vol. 273,
no. 2, pp. 335–339, 1983.
[15] K. J. Barnham, C. L. Masters, and A. I. Bush, “Neurodegen-
erative diseases and oxidatives stress,” Nature Reviews Drug
Discovery, vol. 3, no. 3, pp. 205–214, 2004.
[16] A. A. A. B. White, “The metallobiology of Alzheimer’s
disease: from bench to clinic. Current medical literature,”
Neurology, vol. 22, no. 4, pp. 89–97, 2006.
[ 1 7 ]P .J .C r o u c h ,K .J .B a r n h a m ,A .I .B u s h ,a n dA .R .W h i t e ,
“Therapeutic treatments for Alzheimer’s disease based on
metalbioavailability,”DrugNewsandPerspectives,vol.19,no.
8, pp. 469–474, 2006.
[ 1 8 ]M .R .H y n d ,H .L .S c o t t ,a n dP .R .D o d d ,“ G l u t a m a t e -
mediated excitotoxicity and neurodegeneration in
Alzheimer’s disease,” Neurochemistry International,v o l .
45, no. 5, pp. 583–595, 2004.
[19] M. Eder, K. Becker, G. Rammes et al., “Distribution and
properties of functional postsynaptic kainate receptors on
neocortical layer V pyramidal neurons,” Journal of Neuro-
science, vol. 23, no. 16, pp. 6660–6670, 2003.
[20] J. Lerma, “Roles and rules of kainate receptors in synaptic
transmission,”Nature Reviews Neuroscience,v o l .4 ,n o .6 ,p p .
481–495, 2003.
[21] A. S.Leonard, I. A. Lim,D. E. Hemsworth,M.C. Horne,and
J. W. Hell, “Calcium/calmodulin-dependent protein kinase
II is associated with the N-methyl-D-aspartate receptor,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 96, no. 6, pp. 3239–3244, 1999.
[22] B. K. Andr´ asfalvy and J. C. Magee, “Changes in AMPA
receptor currents following LTP induction on rat CA1
pyramidal neurones,” Journal of Physiology, vol. 559, no. 2,
pp. 543–554, 2004.
[23] V. Derkach, A. Barria, and T. R. Soderling, “Ca/calmodulin-
kinase II enhances channel conductance of α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionate type glutamate
receptors,” Proceedings of the National Academy of Sciences of
the United States of America, vol. 96, no. 6, pp. 3269–3274,
1999.
[24] Z. Wang,J.G. Edwards, N. Riley et al.,“Myosin Vb mobilizes
recycling endosomes and AMPA receptors for postsynaptic
plasticity,” Cell, vol. 135, no. 3, pp. 535–548, 2008.
[25] K. U. Bayer, P. De Koninck, A. S. Leonard, J. W. Hell, and
H. Schulman, “Interaction with the NMDA receptor locks
CaMKII in an active conformation,” Nature, vol. 411, no.
6839, pp. 801–805, 2001.
[ 2 6 ]P .N .L a c o r ,M .C .B u n i e l ,P .W .F u r l o we ta l . ,“ A β oligomer-
induced aberrations in synapse composition, shape, and
density provide a molecular basis for loss of connectivity in
Alzheimer’s disease,” Journal of Neuroscience, vol. 27, no. 4,
pp. 796–807, 2007.
[ 2 7 ]E .M .S n y d e r ,Y .N o n g ,C .G .A l m e i d ae ta l . ,“ R e g u l a t i o n
of NMDA receptor traﬃcking by amyloid-β,” Nature Neuro-
science, vol. 8, no. 8, pp. 1051–1058, 2005.
[28] A. Barria and R. Malinow, “NMDA receptor subunit com-
position controls synaptic plasticity by regulating binding to
CaMKII,” Neuron, vol. 48, no. 2, pp. 289–301, 2005.International Journal of Alzheimer’s Disease 7
[29] F.GardoniandM.DiLuca,“Newtargetsforpharmacological
intervention in the glutamatergic synapse,” European Journal
of Pharmacology, vol. 545, no. 1, pp. 2–10, 2006.
[30] G. E. Hardingham and H. Bading, “Coupling of extrasy-
naptic NMDA receptors to a CREB shut-oﬀ pathway is
developmentally regulated,” Biochimica et Biophysica Acta,
vol. 1600, no. 1-2, pp. 148–153, 2002.
[31] C. Priller, T. Bauer, G. Mitteregger, B. Krebs, H. A. Kret-
zschmar, and J. Herms, “Synapse formation and function is
modulated by the amyloid precursor protein,” The Journal of
Neuroscience, vol. 26, no. 27, pp. 7212–7221, 2006.
[32] A. Deshpande, H. Kawai, R. Metherate, C. G. Glabe, and
J. Busciglio, “A role for synaptic zinc in activity-dependent
aβ oligomer formation and accumulation at excitatory
synapses,” Journal of Neuroscience, vol. 29, no. 13, pp. 4004–
4015, 2009.
[33] B. L. Kelly and A. Ferreira, “β-amyloid-induced dynamin 1
degradation is mediated by N-methyl-D-aspartate receptors
in hippocampal neurons,” J o u r n a lo fB i o l o g i c a lC h e m i s t r y ,
vol. 281, no. 38, pp. 28079–28089, 2006.
[34] M.Bucciantini,E. Giannoni,F. Chiti et al.,“Inherent toxicity
of aggregates implies a common mechanism for protein
misfolding diseases,” Nature, vol. 416,no. 6880, pp. 507–511,
2002.
[35] Y. J. Zhu, H. Lin, and R. Lal, “Fresh and nonﬁbrillar amyloid
β protein(1-40) induces rapid cellular degeneration in aged
human ﬁbroblasts: evidence for AβP-channel-mediated cel-
lular toxicity,” FASEB Journal, vol. 14, no. 9, pp. 1244–1254,
2000.
[36] J. I. Kourie, “Mechanisms of amyloid β protein-induced
modiﬁcation in ion transport systems: implications for
neurodegenerative diseases,” Cellular and Molecular Neuro-
biology, vol. 21, no. 3, pp. 173–213, 2001.
[37] H.Hsieh,J.Boehm,C.Satoet al.,“AMPARremovalunderlies
Aβ-induced synaptic depression and sendritic spine loss,”
Neuron, vol. 52, no. 5, pp. 831–843, 2006.
[ 3 8 ]C .I .S z e ,H .B i ,B .K .K l e i n s c h m i d t - D e M a s t e r s ,C .M .
Filley, and L. J. Martin, “N-Methyl-D-aspartate receptor
subunit proteins and their phosphorylation status are altered
selectively in Alzheimer’s disease,” Journal of the Neurological
Sciences, vol. 182, no. 2, pp. 151–159, 2001.
[39] A. J. Mishizen-Eberz, R. A. Rissman, T. L. Carter, M. D.
Ikonomovic, B. B. Wolfe, and D. M. Armstrong, “Bio-
chemical and molecular studies of NMDA receptor sub-
units NR1/2A/2B in hippocampal subregions throughout
progression of Alzheimer’s disease pathology,” Neurobiology
of Disease, vol. 15, no. 1, pp. 80–92, 2004.
[ 4 0 ]S .E .H o e y ,R .J .W i l l i a m s ,a n dM .S .P e r k i n t o n ,“ S y n a p t i c
NMDA receptor activation stimulates α-secretase amyloid
precursor protein processingandinhibitsamyloid-β Produc-
tion,” Journal of Neuroscience, vol. 29, no. 14, pp. 4442–4460,
2009.
[ 4 1 ]J .W u ,R .A n w y l ,a n dM .J .R o w a n ,“ β-amyloid-(1–40)
increases long-term potentiation in rat hippocampus,” Euro-
pean Journal of Pharmacology, vol. 284, no. 3, pp. R1–R3,
1995.
[ 4 2 ]Q .S .C h e n ,W .Z .W e i ,T .S h i m a h a r a ,a n dC .W .X i e ,
“Alzheimeramyloidβ-peptide inhibitsthelate phaseof long-
term potentiation through calcineurin-dependent mecha-
nisms in the hippocampal dentate gyrus,” Neurobiology of
Learning and Memory,vol. 77, no. 3, pp. 354–371, 2002.
[43] S. A. Lipton, “Failures and successes of NMDA receptor
antagonists: molecular basis for the use of open-channel
blockers like memantine in the treatment of acute and
chronic neurologic insults,” NeuroRx, vol. 1, no. 1, pp. 101–
110, 2004.
[44] K. Vogt, J. Mellor, G. Tong, and R. Nicoll, “The actions
of synaptically released zinc at hippocampal mossy ﬁber
synapses,” Neuron, vol. 26, no. 1, pp. 187–196, 2000.
[ 4 5 ]Y .L i ,C .J .H o u g h ,S .W .S u h ,J .M .S a r v e y ,a n dC .J .
Frederickson, “Rapid translocation of Zn(2+) from presy-
naptic terminals into postsynaptic hippocampal neurons
after physiological stimulation,” Journal of Neurophysiology,
vol. 86, no. 5, pp. 2597–2604, 2001.
[46] J.QianandJ.L.Noebels,“Visualizationoftransmitterrelease
with zinc ﬂuorescence detection at the mouse hippocampal
mossy ﬁbre synapse,” Journal of Physiology, vol. 566, no. 3,
pp. 747–758, 2005.
[47] Y. B. Choi and S. A. Lipton, “Identiﬁcation and mechanism
of action of two histidine residues underlying high-aﬃnity
Zn
2+ inhibition of the NMDA receptor,” Neuron, vol. 23, no.
1, pp. 171–180, 1999.
[48] P. Paoletti, F. Perin-Dureau, A. Fayyazuddin, A. Le Goﬀ,
I. Callebaut, and J. Neyton, “Molecular organization of a
zinc binding N-terminal modulatory domain in a NMDA
receptor subunit,” Neuron, vol. 28, no. 3, pp. 911–925, 2000.
[49] J. Rachline, F. Perin-Dureau, A. Le Goﬀ,J .N e y t o n ,a n d
P. Paoletti, “The micromolar zinc-binding domain on the
NMDA receptor subunit NR2B,” Journal of Neuroscience,v o l .
25, no. 2, pp. 308–317, 2005.
[50] P. Paoletti, P. Ascher, and J. Neyton, “High-aﬃnity zinc
inhibition of NMDA NR1-NR2A receptors,” Journal of
Neuroscience, vol. 17, no. 15, pp. 5711–5725, 1997.
[51] M. L. Mayer, L. Vyklicky, and G. L. Westbrook, “Modulation
of excitatory amino acid receptors by group IIB metal
cations in cultured mouse hippocampal neurones,” Journal
of Physiology, vol. 415, pp. 329–350, 1989.
[ 5 2 ]S .P e t e r s ,J .K o h ,a n dD .W .C h o i ,“ Z i n cs e l e c t i v e l yb l o c k s
the action of N-methyl-D-aspartate on cortical neurons,”
Science, vol. 236, no. 4801, pp. 589–593, 1987.
[53] G. L. Westbrook and M. L. Mayer, “Micromolar concentra-
tions of Zn
2+ antagonize NMDA and GABA responses of
hippocampal neurons,” Nature, vol. 328, no. 6131, pp. 640–
643, 1987.
[ 5 4 ]Y .L i ,C .J .H o u g h ,C .J .F r e d e r i c k s o n ,a n dJ .M .S a r v e y ,
“Induction of mossy ﬁber→CA3 long-term potentiation
requires translocation of synaptically released Zn
2+,” Journal
of Neuroscience, vol. 21, no. 20, pp. 8015–8025, 2001.
[55] C. B. Sindreu, H. Varoqui, J. D. Erickson, and J. P´ erez-
Clausell, “Boutons containing vesicular zinc deﬁne a sub-
population of synapses with low AMPAR content in rat
hippocampus,” Cerebral Cortex, vol. 13, no. 8, pp. 823–829,
2003.
[56] M. L. Schlief and J. D. Gitlin, “Copper homeostasis in the
CNS: a novel link between the NMDA receptor and copper
homeostasis in the hippocampus,” Molecular Neurobiology,
vol. 33, no. 2, pp. 81–90, 2006.
[ 5 7 ]M .L .S c h l i e f ,A .M .C r a i g ,a n dJ .D .G i t l i n ,“ N M D Ar e c e p t o r
activation mediates copper homeostasis in hippocampal
neurons,” Journal of Neuroscience, vol.25, no. 1, pp. 239–246,
2005.
[58] D. E. Hartter and A. Barnea, “Evidence for release of copper
in the brain: depolarization-induced release of newly taken-
up copper,” Synapse, vol. 2, no. 4, pp. 412–415, 1988.
[ 5 9 ]J .K a r d o s ,I .K o v a c s ,F .H a j o s ,M .K a l m a n ,a n dM .S i m o n y i ,
“Nerve endings from rat brain tissue release copper upon
depolarization. A possible role in regulating neuronal8 International Journal of Alzheimer’s Disease
excitability,” NeuroscienceLetters,vol.103,no.2,pp.139–144,
1989.
[60] K. J. Barnham and A. I. Bush, “Metals in Alzheimer’s and
Parkinson’s diseases,” Current Opinion in Chemical Biology,
vol. 12, no. 2, pp. 222–228, 2008.
[ 6 1 ]P .D u t a r ,M .H .B a s s a n t ,M .C .S e n u t ,a n dY .L a m o u r ,
“The septohippocampalpathway:structure andfunction ofa
centralcholinergic system,”Physiological Reviews,v ol.75,no .
2, pp. 393–427, 1995.
[62] J. Winkler, S. T. Suhr, F. H. Gage, L. J. Thal, and L. J.
Fisher, “Essential role of neoecortical acetylcholine in spatial
memory,” Nature, vol. 375, no. 6531, pp. 484–487, 1995.
[ 6 3 ]R .T .B a r t u s ,R .L .D e a n ,B .B e e r ,a n dA .S .L i p p a ,“ T h e
cholinergic hypothesis of geriatric memory dysfunction,”
Science, vol. 217, no. 4558, pp. 408–417, 1982.
[64] J. T. Coyle, D. L. Price, and M. R. DeLong, “Alzheimer’s
disease: a disorder of cortical cholinergic innervation,”
Science, vol. 219, no. 4589, pp. 1184–1190, 1983.
[65] M. Goedert, “Tau protein and the neuroﬁbrillary pathology
of Alzheimer’s disease,” Trends in Neurosciences, vol. 16, no.
11, pp. 460–465, 1993.
[66] E. K. Perry, M. Johnson, J. M. Kerwin et al., “Convergent
cholinergic activities in aging and Alzheimer’s disease,”
Neurobiology of Aging, vol. 13, no. 3, pp. 393–400, 1992.
[ 6 7 ]G .R a n s m a y r ,P .C e r v e r a ,E .C .H i r s c h ,W .B e r g e r ,W .
Fischer, and Y. Agid, “Alzheimer’s disease: is the decrease of
the cholinergic innervation of the hippocampus related to
intrinsic hippocampal pathology?” Neuroscience,v o l .4 7 ,n o .
4, pp. 843–851, 1992.
[68] L. M. Bierer, V. Haroutunian, S. Gabriel et al., “Neurochem-
ical correlates of dementia severity in Alzheimer’s disease:
relative importance of the cholinergic deﬁcits,” Journal of
Neurochemistry, vol. 64, no. 2, pp. 749–760, 1995.
[ 6 9 ] R .S .J o p e ,L .S o n g ,a n dR .E .P o w e r s ,“ C h o l i n e r g i ca c t i v a t i o n
of phosphoinositide signaling is impaired in Alzheimer’s
disease brain,” Neurobiology of Aging, vol. 18, no. 1, pp. 111–
120, 1997.
[70] C. J. Ladner and J. M. Lee, “Pharmacological drug treatment
of Alzheimer disease: the cholinergic hypothesis revisited,”
Journal of Neuropathology and Experimental Neurology,v o l .
57, no. 8, pp. 719–731, 1998.
[ 7 1 ]W .A .P e d e r s e n ,M .A .K l o c z e w i a k ,a n dJ .K .B l u s z t a j n ,
“Amyloid β-protein reduces acetylcholine synthesis in a cell
linederived from cholinergic neuronsofthe basal forebrain,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 93, no. 15, pp. 8068–8071, 1996.
[72] S.Boncristiano,M.E.Calhoun,P.H.Kellyetal.,“Cholinergic
changes in the APP23 transgenic mouse model of cerebral
amyloidosis,”JournalofNeuroscience,vol.22,no.8,pp.3234–
3243, 2002.
[73] D. M. Bowen, C. B. Smith, P. White, and A. N. Davison,
“Neurotransmitter related enzymes andindices ofhypoxia in
seniledementia andother abiotrophies,”Brain, vol.99, no.3,
pp. 459–496, 1976.
[74] P. J. Whitehouse, D. L. Price, and R. G. Struble, “Alzheimer’s
disease and senile dementia: loss of neurons in the basal
forebrain,” Science, vol. 215, no. 4537, pp. 1237–1239, 1982.
[ 7 5 ]O .J .M .V o g e l s ,C .A .J .B r o e r e ,H .J .T e rL a a k ,H .J .T e n
Donkelaar, R. Nieuwenhuys, and B. P. M. Schulte, “Cell loss
and shrinkage in the nucleus basalis Meynert complex in
Alzheimer’s disease,” Neurobiology of Aging,v o l .1 1 ,n o .1 ,p p .
3–13, 1990.
[76] H. Y. Wang, D. H. S. Lee, M. R. D’Andrea, P. A. Peterson, R.
P. Shank, and A. B. Reitz, “β-amyloid binds to α7 nicotinic
acetylcholine receptor with high aﬃnity. Implications for
Alzheimer’s disease pathology,” Journal of Biological Chem-
istry, vol. 275, no. 8, pp. 5626–5632, 2000.
[ 7 7 ] H .Y .W a n g ,D .H .S .L e e ,C .B .D a v i s ,a n dR .P .S h a n k ,“ A m y -
loid peptide Aβ(1–42) binds selectively and with picomolar
aﬃnity to α7 nicotinic acetylcholine receptors,” Journal of
Neurochemistry, vol. 75, no. 3, pp. 1155–1161, 2000.
[78] H. Y. Wang, A. Stucky, J. Liu, C. Shen, C. Trocme-Thibierge,
and P. Morain, “Dissociating β-amyloid from α7 nicotinic
acetylcholine receptor by a novel therapeutic agent, S 24795,
normalizes α7 nicotinic acetylcholine and NMDA receptor
function in Alzheimer’s disease brain,” Journal of Neuro-
science, vol. 29, no. 35, pp. 10961–10973, 2009.
[79] L.G. Costa and D. A.Fox, “A selective decrease ofcholinergic
muscarinic receptors in the visual cortex of adult rats
following developmental lead exposure,” Brain Research,v o l .
276, no. 2, pp. 259–266, 1983.
[80] G. V. W. Johnsonand R. S. Jope, “Aluminum impairs glucose
utilization and cholinergic activity in rat brain in vitro,”
Toxicology, vol. 40, no. 1, pp. 93–102, 1986.
[81] W. S. Webster and A. A. Valois, “The toxic eﬀects ofcadmium
on the neonatal mouse CNS,” Journal of Neuropathology and
Experimental Neurology, vol. 40, no. 3, pp. 247–257, 1981.
[82] C. Winder and I. Kitchen, “Lead neurotoxicity: a review
of the biochemical, neurochemical and drug induced
behavioural evidence,” Progress in Neurobiology, vol. 22, no.
1, pp. 59–87, 1984.
[83] P. Moingeon, J. M. Bidart, and G. F. Alberici, “In vivo
modulation of muscarine receptors in rat brain by acute lead
intoxication,” Toxicology, vol. 31, no. 2, pp. 135–142, 1984.
[84] S. Schulte, W. E. M¨ uller, and K. D. Friedberg, “In vivo
exposure to lead does not inﬂuence muscarinic receptors in
the frontalcortex ofthe mousebrain,”Toxicology, vol.93,no.
2-3, pp. 99–112, 1994.
[ 8 5 ]C .G o t t i ,D .C a b r i n i ,E .S h e r ,a n dF .C l e m e n t i ,“ E ﬀects of
long-term in vitro exposure to aluminum, cadmium or lead
on diﬀerentiation and cholinergic receptor expression in a
human neuroblastoma cell line,” Cell Biology and Toxicology,
vol. 3, no. 4, pp. 431–440, 1987.
[86] G. R. Lewin and Y. A. Barde, “Physiology of the neu-
rotrophins,” Annual Review of Neuroscience, vol. 19, pp. 289–
317, 1996.
[ 8 7 ]E .S .L e v i n e ,C .F .D r e y f u s ,I .B .B l a c k ,a n dM .R .P l u m -
mer, “Brain-derived neurotrophic factor rapidly enhances
synaptic transmission in hippocampal neurons via postsy-
naptic tyrosine kinase receptors,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 92,
no. 17, pp. 8074–8077, 1995.
[88] H. Kang and E. M. Schuman, “Long-lasting neuratrophin-
induced enhancement of synaptic transmission in the adult
hippocampus,” Science, vol. 267, no. 5204, pp. 1658–1662,
1995.
[ 8 9 ]G .C h e n ,R .K o l b e c k ,Y .A .B a r d e ,T .B o n h o e ﬀer, and A.
Kossel, “Relative contribution of endogenous neurotrophins
in hippocampal long- term potentiation,” Journal of Neuro-
science, vol. 19, no. 18, pp. 7983–7990, 1999.
[90] A. H. Kossel, S. B. Cambridge, U. Wagner, and T. Bonhoeﬀer,
“A caged Ab reveals an immediate/instructive eﬀect of BDNF
during hippocampal synaptic potentiation,” Proceedings of
the National Academy of Sciences of the United States of
America, vol. 98, no. 25, pp. 14702–14707, 2001.
[91] M. Barbacid, “Structural and functional properties of the
TRK family of neurotrophin receptors,” Annals of the New
York Academy of Sciences, vol. 766, pp. 442–458, 1995.International Journal of Alzheimer’s Disease 9
[92] E. J. Huang and L. F. Reichardt, “Trk receptors: roles in neu-
ronal signal transduction,” Annual Review of Biochemistry,
vol. 72, pp. 609–642, 2003.
[93] R. Lee, P. Kermani, K. K. Teng, and B. L. Hempstead,
“Regulation of cell survival by secreted proneurotrophins,”
Science, vol. 294, no. 5548, pp. 1945–1948, 2001.
[94] F. S. Lee, R. Rajagopal, A. H. Kim, P. C. Chang, and M. V.
Chao, “Activation of Trk neurotrophin receptor signaling by
pituitary adenylate cyclase-activating polypeptides,” Journal
ofBiological Chemistry,vol.277,no.11,pp. 9096–9102,2002.
[95] B.Connor,D.Young,Q.Yan,R. L.M.Faull,B.Synek,andM.
Dragunow, “Brain-derived neurotrophic factor is reduced in
Alzheimer’s disease,” Molecular Brain Research, vol.49,no.1-
2, pp. 71–81, 1997.
[ 9 6 ]H .S .P h i l l i p s ,J .M .H a i n s ,M .A r m a n i n i ,G .R .L a r a m e e ,S .
A. Johnson, and J. W. Winslow, “BDNF mRNA is decreased
in the hippocampus of individuals with Alzheimer’s disease,”
Neuron, vol. 7, no. 5, pp. 695–702, 1991.
[97] K. D. Murray, C. M. Gall, E. G. Jones, and P. J. Isackson,
“Diﬀerential regulation of brain-derived neurotrophic factor
and type II calcium/calmodulin-dependent protein kinase
messenger RNA expression in Alzheimer’s disease,” Neuro-
science, vol. 60, no. 1, pp. 37–48, 1994.
[98] M. Narisawa-Saito, K. Wakabayashi, S. Tsuji, H. Takahashi,
and H. Nawa, “Regional speciﬁcity of alterations in NGF,
BDNF and NT-3 levels in Alzheimer’s disease,” NeuroReport,
vol. 7, no. 18, pp. 2925–2928, 1996.
[ 9 9 ]A .S a l e h i ,J .V e r h a a g e n ,P .A .D i j k h u i z e n ,a n dD .F .S w a a b ,
“Co-localization of high-aﬃnity neurotrophin receptors in
nucleus basalis of Meynert neurons and their diﬀerential
reduction in Alzheimer’s disease,” Neuroscience,v o l .7 5 ,n o .
2, pp. 373–387, 1996.
[100] I. Ferrer, C. Mar´ ın, M. J. Rey et al., “BDNF and full-length
andtruncatedTrkBexpressioninAlzheimerdisease.Implica-
tionsintherapeuticstrategies,”JournalofNeuropathologyand
Experimental Neurology, vol. 58, no. 7, pp. 729–739, 1999.
[101] S. Capsoni, C. Tiveron, D. Vignone, G. Amato, and A.
Cattaneo, “Dissecting the involvement of tropomyosin-
related kinase A and p75 neurotrophin receptor signaling in
NGF deﬁcit-induced neurodegeneration,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 107, no. 27, pp. 12299–12304, 2010.
[102] J. H. Jung, M. H. Park, S. Y. Choi, and J. Y. Koh, “Activation
of the Trk signaling pathway by extracellular zinc. Role of
metalloproteinases,”J o u r n a lo fB i o l o g i c a lC h e m i s t r y , vol. 280,
no. 12, pp. 11995–12001, 2005.
[103] C. E. A. Corona, “Dietary zinc supplementation of 3xTg-AD
mice increases BDNF levels and prevents cognitive deﬁcits as
well as mitochondrial dysfunction,” Cell Death and Disease,
vol. 1, article e91, 2010.
[104] G. M. Ross, I. L. Shamovsky, G. Lawrance et al., “Zinc
alters conformationandinhibits biological activities ofnerve
growth factor and related neurotrophins,” Nature Medicine,
vol. 3, no. 8, pp. 872–878, 1997.
[105] J. H. Jung, MI. H. Park, and J. Y. Koh, “Copper activates
TrkB in cortical neurons in a metalloproteinase-dependent
manner,”Journal of Neuroscience Research, vol.85,no.10, pp.
2160–2166, 2007.
[106] Y.Z.Huang,E.Pan,Z.Q.Xiong,andJ.O.McNamara,“Zinc-
mediated transactivation of TrkB potentiates the hippocam-
pal mossy ﬁber-CA3 pyramid synapse,” Neuron, vol. 57, no.
4, pp. 546–558, 2008.
[107] A. R. White, T. Du, K. M. Laughton et al., “Degradation
of the Alzheimer disease amyloid β-peptide by metal-
dependent up-regulation ofmetalloproteaseactivity,” Journal
of Biological Chemistry, vol. 281, no. 26, pp. 17670–17680,
2006.
[108] P. S. Donnelly, A. Caragounis, T. Du et al., “Selective
intracellular release of copper and zinc ions from
bis(thiosemicarbazonato) complexes reduces levels of
Alzheimer disease amyloid-β peptide,” Journal of Biological
Chemistry, vol. 283, no. 8, pp. 4568–4577, 2008.
[109] P. J. Crouch, W. H. Lin, P. A. Adlard et al., “Increasing Cu
bioavailability inhibits Aβ oligomers and tau phosphoryla-
tion,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 106, no. 2, pp. 381–386, 2009.
[110] K. A. Price, G. Filiz, A. Caragounis et al., “Activation of
epidermal growth factor receptor by metal-ligand complexes
decreases levels of extracellular amyloid beta peptide,” Inter-
national Journal of Biochemistry and Cell Biology, vol. 40, no.
9, pp. 1901–1917, 2008.
[111] K. A. Price, A. Caragounis, B. M. Paterson et al., “Sustained
activation of glial cell epidermal growth factor receptor by
bis(thiosemicarbazonato)metal complexes is associatedwith
inhibition of protein tyrosine phosphatase activity,” Journal
of Medicinal Chemistry, vol. 52, no. 21, pp. 6606–6620, 2009.